Stock CONCORDBIO CONCORD BIOTECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Concord Biotech Limited

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:40:47 2024-05-16 am EDT 		5-day change 1st Jan Change
1,458 INR -1.96% Intraday chart for Concord Biotech Limited -6.11% -0.92%
Mar. 18 Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index CI
Mar. 06 Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator MT

Valuation

Fiscal Period: March 2024 2025 2026
Capitalization 1 152,557 - -
Enterprise Value (EV) 1 151,927 150,919 149,514
P/E ratio 50.5 x 39.5 x 30.5 x
Yield 0.43% 0.53% 0.67%
Capitalization / Revenue 15.4 x 12.4 x 10.1 x
EV / Revenue 15.3 x 12.2 x 9.88 x
EV / EBITDA 35.9 x 28.2 x 22.2 x
EV / FCF 167 x 56.2 x 46.1 x
FCF Yield 0.6% 1.78% 2.17%
Price to Book 9.97 x 8.32 x 6.84 x
Nbr of stocks (in thousands) 104,616 - -
Reference price 2 1,458 1,458 1,458
Announcement Date - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 9,917 12,327 15,129
EBITDA 1 - 4,228 5,348 6,731
EBIT 1 - 3,647 4,799 6,137
Operating Margin - 36.78% 38.93% 40.56%
Earnings before Tax (EBT) 1 - 3,974 5,091 6,602
Net income 1 2,401 3,009 3,871 4,988
Net margin - 30.34% 31.4% 32.97%
EPS 2 22.95 28.85 36.88 47.82
Free Cash Flow 1 - 911.5 2,684 3,245
FCF margin - 9.19% 21.78% 21.45%
FCF Conversion (EBITDA) - 21.56% 50.19% 48.21%
FCF Conversion (Net income) - 30.29% 69.34% 65.06%
Dividend per Share 2 - 6.280 7.755 9.705
Announcement Date 7/1/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 - 630 1,638 3,043
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - 912 2,684 3,245
ROE (net income / shareholders' equity) - 21.4% 22.5% 24.2%
ROA (Net income/ Total Assets) - 19% 19% 21%
Assets 1 - 15,837 20,374 23,752
Book Value Per Share 2 - 146.0 175.0 213.0
Cash Flow per Share - - - -
Capex 1 - 1,433 550 600
Capex / Sales - 14.45% 4.46% 3.97%
Announcement Date 7/1/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,458 INR
Average target price
1,597 INR
Spread / Average Target
+9.50%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CONCORD BIOTECH LIMITED Stock Concord Biotech Limited
-0.92% 1.86B
CSL LIMITED Stock CSL Limited
+0.10% 91.42B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.16% 41.08B
BIOGEN INC. Stock Biogen Inc.
-11.10% 34.26B
UCB Stock UCB
+53.99% 25.27B
INCYTE CORPORATION Stock Incyte Corporation
-9.41% 12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.25% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.00% 11.42B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 9.16B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-6.90% 8.22B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock
  4. Financials Concord Biotech Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW